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CR3 (CD11b/CDl8) EXPRESSES ONE BINDING SITE FOR
Arg-Gly-Asp-CONTAINING PEPTIDES AND A SECOND SITE
FOR BACTERIAL LIPOPOLYSACCHARIDE
BY SAMUEL D. WRIGHT, SUSAN M. LEVIN, MICHELLE T. C. JONG,
ZAVE CHAD,* AND LYNDA G. KÀBBASHI
From The Laboratory of Cellular Physiology and Immunology, The Rockefeller University,
New York, New York 10021; the *Ste. Justine Hospital, Montreal University; and
the lRoyal Victoria Hospital, McGill University, Montreal, Quebec
Human phagocytes express a family ofcell surface glycoproteins known as LFA-1
(CD11a/CD18), CR3 (CDllb/CD18), and p150,95 (CD11c/CD18) (1). Each of these
receptors is a dimer composed of a 0 chain (CD18) that is identical in all three
members and a noncovalently associated a chain (CDll) that is unique to each mol-
ecule. CR3 was first recognized as a receptor for the surface-bound complement
protein C3bi (2), but was later shown to function in the recognition ofseveral other
particles, including zymosan (3), Escherichia colt' (4), and Histoplasma capsulatum (5)
and in the binding ofpolymorphonuclearleukocytes (PMN)' to protein-coated sur-
faces (6). Ross et al. (3) first suggested that CR3 has two distinct binding sites be-
cause certain anti-CR3 mAbs that blocked the binding ofC3bi did not block the
binding of zymosan and vice versa. Dana et al. (6) later showed that the anti-CR3
mAb 904blocked the binding ofPMN to protein-coated plastic, but not the binding
ofC3bi. We have extended these studies by using ligands of defined structure to
define and map the binding sites of CR3.
Previous workfrom thislaboratoryhas characterized two structurally distinct classes
ofligand that bind CR3. The firstclassofligand is exemplified by the proteins C3bi,
fibrinogen, and Leishmania gp63 . CR3 binds these proteins by recognizing a re-
gion that contains the amino acid sequence Arg-Gly-Asp in C3bi and gp63 (7, 8),
or the structurally similar Lys-x-x-Gly-Asp in fibrinogen (9). The second class of
ligand is exemplified by bacterial LPS. CR3 (as well as LFA-1 and p150,95) recog-
nizes rough LPS, lipid A, and the biosynthetic precursor 0-(2-amino-2-deoxy-0-D-
glycopyranosyl)-(1-6)-2-amino-2-deoxy-2-D-glucose acetylated at positions 2, 3, 2',
and 3' with 0-hydroxymyristoyl moieties and bearing phosphate groups at positions
1 and 4' (lipid IVa) (4).
Since peptides containing Arg-Gly-Asp are structurally different from LPS, we
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sought to determine ifthese two ligands interact with the same or different binding
sites on CR3. Here we show that an mAb against CR3, which blocks the binding
of C3bi, does not block the binding of LPS, and another monoclonal anti-CR3, which
blocks binding of lipid IVa-coated erythrocytes, does not block binding of C3bi-
coated erythrocytes. Further, synthetic peptides that competitively inhibit the binding
of C3bi do not inhibit, but rather enhance, the binding ofIVa. Thus, separate binding
sites are used to recognize the two classes of ligand. Here we also confirm that both
binding sitesare on the same molecule since cells from patients with a genetic deficiency
in CD18 fail to bind both C3bi and lipid IVa.
Materials and Methods
Subjects.
￿
Three patients of French Canadian origin with CD18 deficiency (also known
as leukocyte adhesion deficiency [LAD]) have been recently describéd2. All were 2-4 yr of
age at the time of this study, and all had a history of recurrent infections and extreme leu-
kocytosis.
Peptides.
￿
Peptide LIO (LGGAKQAGDV), based on residues 402-411 of the y chain of
human fibrinogen (Fg), was synthesized by Peninsula Laboratories, Inc. (Belmont, CA). An
inactive analogue of L10, AcLIO, was prepared by acetylating lysine 406 as described (9).
Both L10 and AcLlO were repurified by HPLC on a reverse phase column. Peptides C3-12
(TRYRGDQDATMS), based on residues 1390-1401 of human C3, was a generous gift of
Dr. M. Ginsberg (La Jolla, CA).
Antibodies.
￿
mAbs OKM1 (IgG2b) and OKM10 (IgG2b), directed against the a chain
(CDllb) of CR3 (2) were a gift of Dr. G. Goldstein, (Ortho Pharmaceutical, Raritan, NJ);
mAb 904 (IgGI), also directed against the a chain (CDllb) of CR3 (10) was a gift of Dr.
J. Griffin (Dana-Farber Cancer Center, Boston, MA); mAb IB4 (IgG2a), directed against
the 0 chain (CD18) of CR3, LFA-1, and p150,95, was as described (2); and mAb 3G8 (IgGI),
directed against the low avidity Fc receptor ofneutrophils (FcRIII, CD16) was as described (11).
mAbs IB4, 904, OKM10, and F(ab)2 antimurine IgG (Boehringer Biochemicals, Indi-
anapolis, IN) were labeled with "sI by the iodogen procedure (12) to sp act of 0.5-5 x 10'
cpm/wg.
Cells.
￿
PMN were purified from fresh human blood on Ficoll-Hypaque gradients (13).
As observed by other investigators, PMN from the CD18-deficient patients bound very poorly
to protein-coated surfaces (data not shown), but we could obtain normal high plating efficiency
(>90%) by adding the cells to uncoated Terasaki microtest wells as follows. 10,000 PMN in
HAP buffer (Dulbecco's PBS containing 0.5 mg/ml human serum albumin, 3 mM glucose,
and 0.3 u/ml aprotinin) were added to uncoated wells of Terasaki tissue culture trays and
incubated at 37°C for 30 min. The resulting monolayers were stable to repeated washes.
Sheep erythrocytes were coated with C3b (EC3b), C3bi (EC3bi), or IgG (EIgG) as previ-
ously described (14). Sheep erythrocytes were coated with rough (Re) LPS (ELPS) or lipid
IVa (EIVa) as described (4). E. colt' K12 (strain MC1061) was grown and labeled with fluores-
cein as previously described (4).
Attachment of Ligand-coated Particles to PMN
￿
Monolayers of PMN were produced as de-
scribed above. Where indicated, cells were incubated for an additional 10 min at 37°C with
PMA (30 ng/ml) or phorbol dibutyrate (PDB) (300 ng/ml). The PUB was then washed away
by extensive rinsing of the plate in PBS followed by a 20-min incubation at 20°C in a large
volume of HAP. In some experiments, monolayers ofPMN were then incubated with mAbs
for 15 min at 0°C. Ligand-coated erythrocytes and the indicated peptides were added to the
monolayers, erythrocytes were allowed to settle for 15 min at 0°C, and the plate was warmed
to 37'C for 15 min. Unattached erythrocytes were removed by washing, and binding oferythro-
cytes to PMN was scored by phase contrast microscopy as described (14). Binding of E. colt'
2 Detmers, P. A., S. D. Wright, E. Olsen-Egbert, R. Adamowski, Z. Chad, L. G. Kabbash, and Z. A.
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was assessed by a similar method as previously described (4). Results are reported as attach
ment index, the number of erythrocytes or E. coli per 100 PMN.
Expression of Cell Surface CR3.
￿
Monolayers of PMN were established, pulsed with PDB
as described above, then treated with antibodies as described in the text. To measure the amount
of cell surface CR3, cells were cooled to 0°C and incubated for 50 min with 50 ug/ml anti-
CR3 (OKM10 or 904). The presence of anti-receptor antibody bound to the cell surface was
then determined by measuring the binding of 1251 anti-mouse F(ab)2 as described (15). Back-
ground binding was determined in parallel wells from which anti-CR3 was omitted. Parallel
experiments used fluoresceinated F(ab)2 in place of the iodinated F(ab)2 anti-mouse IgG to
visualize the cell surface CR3.
Results
Phagocytes Deficient in the CD18 Complex Fail to Bind ON, E. coli, and LPS.
￿
We have
identified three LAD patients whose leukocytes are nearly devoid of all members
of the CD18 complex. Less than 4°jo of normal levels of LFA-1, CR3, and p150,95
are expressed on the PMN2 . These cells exhibited normal binding of EC3b and
EIgG (Table I) as expected by their normal expression of CRI and FcR2 and failed
to bind EC3bi as expected from their lack of CR3. The capacity of CR3 to bind
EC3bi is dramatically enhanced by treatment of normal PMN with phorbol esters
(15). Treatment of PMN from the LAD patients, however, failed to promote binding
of EMU
To confirm that CD18 is necessary for the recognition of LPS, we measured the
binding ofELPS and unopsonized E. coli, both ofwhich bind to phagocytes via LPS.
PMN from the CD18-deficient patients failed to bind E. coli, ELPS, or EIVa (Table
TABLE I
Attachment of Ligand-coated Particles to PMNfrom Patients
Deficient in CD18
Attachment index
Exp. Subject
1
￿
Patient 1
Control 1
Control 2
2
Patient 1
￿
395
￿
1 .9
￿
16
Patient 2
￿
508
￿
2.0
￿
2
Control 1
￿
364
￿
182
￿
63
Control 2
￿
371
￿
258
￿
55
3
￿
EIgG
￿
EC3bi
￿
EC3bi + PMA EIVa ELPS
Patient 2
￿
552
￿
5 .0
￿
9
￿
1.3
￿
7
Patient 3
￿
579
￿
5 .6
￿
6.3
￿
3.7
￿
4.1
Control 1
￿
552
￿
116
￿
760
￿
168
￿
44
Control 2
￿
800
￿
163
￿
888
￿
370
￿
102
Monolayers ofPMN were established on uncoated tissue plastic surfaces. Where
indicated, PMA (30 ng/ml) was added for 10 min at 37°C. The indicated parti-
cles were added and binding to PMN was determined after a 30-min incubation
at 37°C . Data are reported as the attachment index, the number oferythrocytes
bound per 100 PMN. These results are confirmed in two additional experiments
(not shown).
EC3b EC3bi EC3bi + PMA EIVa E. coli
406 1 .5 3.8 5.8 16
273 86 832 205 223
370 90 770 201 380
EC3b EC3bi + PMA ELPS178
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I). These data confirm the hypothesis that members of the CD18 family function
to bind LPS.
Separate Epitopes on CR3Mediate BindingofON andLPS
￿
We asked whether LPS
binds to CR3 at a site distinct from the site that recognizes C3bi. Monolayers of
PMN were stimulated withPDB to maximally enhancethe bindingactivity ofCR3
for C3bi (15). Cells were cooled, incubated with a panel ofmAbs against the a chain
ofCR3, and ligand-coated erythrocytes were added. mAb 904 against the a chain
ofCR3 effectively blocked the binding ofEIVa (Table II). These data confirm the
role of the CD18 family in the recognition of LPS. They also suggest that CR3 is
the predominant receptor for LPS on PMN and that p150,95 and LFA-1 make a
minor contribution. This is consistent with the observation that CR3 is far more
abundant on phorbol-stimulated PMN than either LFA-1 or p150,95 (1).
Though mAb 904 inhibited binding of EIVa, it did not inhibit the binding of
EC3bi. In contrast, a second mAb against the a chain ofCR3, OKM10, effectively
inhibited the binding ofEC3bi but did not inhibit binding ofEIVa (Table II). The
inhibition observed was unlikely to be due to masking ofthe cell surface since mAb
3G8, directed against the FeRIII ofPMN, hadnoeffect onadhesion, and Fc receptors
are more abundant on the cell surface than CR3 (15). More importantly, a third
mAb against the a chain ofCR3, OKM1, did not inhibitbinding ofEC3bi or EIVa.
These data suggest that CR3 expresses two different epitopes, one that binds LPS
and is recognized by mAb 904, and a second that recognizes C3bi and other pro-
teinaceous ligands and is recognized by mAb OKM10.
904andOKMIOBindSeparate Epitopes.
￿
Weconfirmed that904 and OKM10 bind
separate epitopes by measuringtheir ability to compete for bindingto PMN. A 50-
fold excess ofunlabeled 904 had no effect on the binding ofradioiodinated OKM10
toPMN (Table III). Similarly, a 50-fold excess ofOKM10 did not affect the binding
of radioiodinated 904 to PMN.
We also determined whether incubation of PMN at 37°C with either OKM10
TABLE II
The Two Binding Spec cities of CR3 Are Inhibited by Different
Monoclonal Antireceptor Antibodies
Monolayers of PMN were established by plating cells for 35 min at 37°C then
pulsing for 10 min at 37" -an i -`)B. To prevent the decline in receptor activi-
ty observed during prolonged stimulation with phorbol esters, the PDB was washed
from the cells with a 20-min incubation at 20°C in a large excess of HSA-
containing buffer as previously described (15). Cells were incubated for 15 min
at 0°C with mAbs, ligand-coated erythrocytes were added, and the attachment
index was scored as described in Materials and Methods. All antibodies were
added as ascites fluids diluted to yield a final concentration of -100 ug/ml of
IgG. This experiment is representative of seven studies. Similar results were ob-
tained with purified Igs used at 25 wg/ml.
mAb EC3bi
Attachment index
EIVa EC36
Control 993 206 733
3G8 938 302 888
OKM 1 848 263 915
OKM 10 215 234 815
904 730 28 817or 904 caused redistribution of CR3. PMN were incubated with or without these
antibodies for 30 min at 37°C exactly as described in Table II, then expression of
CR3 was measured as described in Materials and Methods. Incubation of PMN
at 37°C with either OKM10 or 904 caused no change in the amount ofcell surface
CR3 (not shown). The mAbs, thus, were unlikely to have caused internalization
orshedding ofCR3. Parallel experiments monitored the distribution ofcell surface
CR3 by immunofluorescence. In all cases, CR3 was observed to be uniformly dis-
tributed on the cell surface. Thus, at the resolution offluorescence microscopy, nei-
ther antibody caused changes in the distribution of CR3.
SyntheticPeptides that Inhibit BindingofEC3biDo notInhibit BindingofEIVa.
￿
To confirm
that C3bi and LPS bind to CR3 at distinct sites, a synthetic 12 amino acid peptide
correspondingto residues 1390-1401 ofhumanC3 (previously implicated as therec-
ognition sequence inC3bi [7, 9]) wasused to competitivelyinhibitbindingofEC3bi
to stimulated PMN. This peptide, C3-12, strongly inhibited binding ofEC3bi with
half-maximal inhibition at concentrations of-0.4 mg/ml (Fig. 1). In parallel assays,
C3-12 did not inhibit the bindingofEC3b toCRI on PMN. Most importantly, 03-
12 did not inhibit binding of EIVa. Rather, this peptide caused a strong enhance-
ment ofthe binding ofEIVa with adose response that corresponded to that for inhi-
bition ofbinding of EC3bi. Thus, ligation ofthe C3bi binding site with a soluble
ligand, C3-12, enhances the binding efficiency of the LPS binding site.
TABLE III
mAb OKM10 and 904 Do not Compete far the Same Binding Site on CR3
PMA-stimulated PMN were incubated with 1 Vg/ml 1251-OKM10 or 1251-904
in the presence of 50 ug/ml of the indicated mAbs. After 60 min at 0°C, cells
were washed and cell-associated radioactivity was counted.
0 0.25 0.5
￿
I
￿
2
C3-12 (mg/ml)
(TRYRGDQDATMS)
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FIGURE 1.
￿
A synthetic peptide from the recog-
nition site of C3bi inhibits the binding of EC3bi
to PMN but enhances the binding of EIVa.
Monolayers ofPMN were established, pulsed with
PDB, and washed. The binding of EC3bi (O),
EIVa (x), and EC3b (EI) was measured in the
presence of the indicated concentrations of pep-
tide C3-12 . This experiment is representative of
three separate studies.
Competitor Binding of 1251-OKM10 Binding of 1231-904
- 3,829 5,772
904 3,867 600
OKM10 159 4,631180
￿
CR3 HAS TWO DISTINCT BINDING SITES
To confirm the specificity ofthe results with C3-12, additional inhibitory peptides
were used. We have recently shown that CR3 recognizes not only C3bi but also
fibrinogen, and that peptides based on the sequence of Fg recognized by CR3 in-
hibit bindingofboth Fg and C3bi to CR3 (9). The recognition sequence in Fg does
not contain Arg-Gly-Asp, but an alternative sequence in which the positive charge
of Arg is supplied by a nearby Lys group. Chemical acetylation of that Lys group
abolishes the activity of the peptides based on the Fg sequence. A decamer based
on the recognition sequence of Fg, L10, effectively inhibited binding of EC3bi to
PMN and enhanced the binding of EIVa with a similar dose dependence (Fig. 2) .
The specificity of these effects is confirmed by the observation that an analogous
peptide, AcL10, in which the Lys group is acetylated, neither blocked binding of
EC3bi nor enhanced binding of EIVa. These data confirm that occupation of the
C3bi and Fg bindingsite of CR3 does notblock, butinstead enhances bindingof EIVa.
Discussion
We confirm here that members of the CD18 family of receptors on PMN are re-
quired for recognition of bacterial LPS. A genetic deficiency in CD18 renders cells
incapableofbindingboth EC3bi andELPS (Table I). Thebindingsite used to recog-
nize LPS, however, is distinct from that for C3bi. mAbs against CR3 that inhibit
the binding of ELPS do not inhibit the binding of EC3bi and vice versa(Table 11).
Further, synthetic peptides that competitively inhibit the binding of EC3bi do not
inhibit binding of ELPS. Rather, these peptides enhance the binding of LPS (Figs.
1 and 2). Thus, although the binding sites for C3bi and LPS are separate, they are
functionally linked.
The binding site for C3bi functions in the recognition of not only C3bi but also
Leishmania gp63 (8), Fg (9), and an undefined structure on endothelial cells (16).
Binding of each of these ligands is inhibited by mAb OKM10 but not by mAb 904.
Further, binding of all of these ligands can be inhibitedby a similar set of synthetic
peptides. For example, peptides based on the recognition sequence of Fg competi-
EC3bi
1,600-
FIGURE 2.
￿
Effect of peptidesbased on
1,400 \
￿
therecognition sequence of fibrinogen
x 200
￿
X
￿
on the bindingof EC3bi andEIVa to
a1
￿
EC3b
￿
PMN. The binding of EC3bi (x),
-_.- E_ Cab o
￿
°
￿
EIVa (0), and EC3b (A) to PDB-
1,000
￿
stimulated PMNwasmeasured in the
800
￿
a
￿
presence of the indicated concentra-
tionsofsynthetic peptides. LIO, based
on the COOH terminus oftheychain á 600
￿
ofFg, inhibited bindingof EC3biand
400
￿
enhanced thebindingof EIV4. Acety-
t~o
￿
\X
￿
lation ofthelysine groupofLIOyields
200-/
￿
EC3bi
￿
E Na
￿
O
￿
a peptide, AcLIO, with no inhibitory
activity. This experiment is represen-
tative of three separate studies.
0.25 0.5
￿
1
￿
2
￿
0.2505
￿
1
￿
2
LIO (mg/ml)
￿
AcL10(mg/ml)
(LGGAKOAGDV) (LGGAacKOAGDV)WRIGHT ET AL.
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tively inhibit the binding of Fg, C3bi (9), gp63 (8), and binding of PMN to en-
dothelial cells (16). It thus appears that this binding site serves for several structur-
ally similarpeptide ligands. Thea chain of CR3 contributes strongly to the specificity
of this binding site since C3bi and gp63 are not bound by LEA-1 and p150,95, receptors
that differ from CR3 in the identity of the a chain.
In contrast, the binding site for LPS on the CD18 family appears affected little
by the identity ofthe a chain since LFA-1, CR3, and p150,95 exhibit equivalent ability
to bind LPS (4). The precise structural features recognized by the LPS binding site
are not known, and this site may function in recognition of othermolecules in addi-
tion to LPS. For example, H. capsulatum is recognized by all three members of the
CD18 family (5), and a component of the cell wall of this yeast may thus also be
recognized by the "LPS" binding site.
The presence of two binding sites, one for peptide and a second for lipids, may
be a common property of receptors related to the CD18 family. CD18 is a member
of a structurally related superfamily of adhesion-promoting receptors termed Inte-
grins (17). Members of this superfamily recognize ligands that contain the sequences
Arg-Gly-Asp or Lys-x-x-Gly-Asp. For example, the vitronectin receptor recognizes
the triplet Arg-Gly-Asp in vitronectin (18), and gpIIb/IIIa of platelets recognizes
both asequence in fibronectin containing Arg-Gly-Asp and a sequence in fibrinogen
containing the sequence Lys-Gln-Ala-Gly-Asp (19). The vitronectin receptor exhibits
an additional binding site that recognizes ganglioside GD2 (20). Gangliosides are
structurally similar to LPS in that both species are amphipathic with a strongly an-
ionic hydrophilic group. The binding site on CD18 for LPS may thus be the evolu-
tionary homologue of the binding site on the vitronectin receptor for GD2. It is
not known whether the vitronectin receptor can bind bacterial LPS.
The ability of a single receptor to recognize two distinct ligands is not unique
to the integrins. The insulin-like growth factor II receptor binds both insulin-like
growth factor II and mannose-6-phosphate (21), and the bacterial membrane pro-
tein Tar mediates independent chemotactic responses to aspartate and maltose via
distinct binding sites (22). In the case of insulin-like growth factor II, binding of
the twoligandsis cooperative. While the precisebiological significance ofmultifaceted
receptors remains unclear, this property may allow the sensitivity of cells to an in-
dividual ligand to be controlled by a second or regulatory ligand.
Summary
Polymorphonuclear leukocytes (PMN) from three patients deficient in the CD18
family of receptors (LFA-1, CR3, and p150,95) exhibitedan inabilityto bind erythro-
cytes coated with C3bi or bacterial LPS. These observations confirm that the CD18
family, and CR3 in particular, can bind the structurally dissimilar molecules C3bi
and LPS. Further studies showed that LPS and C3bi bind to CR3 at distinct sites.
mAb OKM10 against CR3 blocked binding of C3bi to PMN but did not block the
bindingof LPS. In contrast, mAb 904, directed against a different epitope on CR3,
blockedbindingofLPSto PMNbutnotbindingofC3bi, thus suggesting that different
regions of CR3 were involved in binding these two ligands. In addition, synthetic
peptides based on the sequence in C3bi recognized by CR3 competitively blocked
the binding of C3bi to CR3 but did not block the binding of LPS. Rather, occupa-
tion of the peptide binding site on CR3 by the synthetic peptides enhanced binding182
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of LPS. These results indicate that CR3 has two distinct binding sites, one that recog-
nizes ligands composed of protein and a second that recognizes LPS.
We wish to thank Drs. Patricia A. Detmers and Ralph M. Steinman for critical reading of
the manuscript.
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